– Reuters
Sermonix Pharmaceuticals’ Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pha…
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly
